Biodesix to present new data on nodify lung® testing at chest 2023 annual meeting

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the chest annual meeting 2023 in honolulu, hawaiʻi. these presentations will provide new insight on the clinical utility and real-world impact of the nodify cdt and nodify xl2 tests in the comprehensive management of lung nodules. the first abstract, titled "real-world impact of a blood-based integrated classifier.
BDSX Ratings Summary
BDSX Quant Ranking